Open AccessIxekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
Author(s) -
Liu Yating,
Wang Shangshang
Publication year - 2023
Publication title -
skin health and disease
Language(s) - English
Resource type - Journals
ISSN - 2690-442X
DOI - 10.1002/ski2.139
Subject(s) - pityriasis rubra pilaris , medicine , ixekizumab , vaccination , dermatology , acitretin , immunology , psoriasis , secukinumab , psoriatic arthritis
Abstract Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin‐17A inhibitor.